BNRNasdaqServices-Medical Laboratories

Burning Rock Biotech Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026

$12.29−0.61 (-4.73%)

Close on Oct 19, 2026

Community

Notes and questions about Burning Rock Biotech from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Burning Rock Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on May 15, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BNR.

Revenue growth4.6% · median 42.7%

Gross margin74.7% · median 68.1%

Operating margin-10.2% · median 10.9%

Net margin-10.3% · median 9.5%

Advertisement
300 × 250